Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Revenue (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Revenue for 13 consecutive years, with -$4171.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 312.16% year-over-year to -$4171.0, compared with a TTM value of $427406.0 through Dec 2025, down 16.13%, and an annual FY2025 reading of $31779.0, down 93.76% over the prior year.
  • Revenue was -$4171.0 for Q4 2025 at Abvc Biopharma, down from $795950.0 in the prior quarter.
  • Across five years, Revenue topped out at $795950.0 in Q3 2025 and bottomed at -$234960.0 in Q1 2025.
  • Average Revenue over 5 years is $120750.2, with a median of $28550.5 recorded in 2021.
  • The sharpest move saw Revenue soared 2350.74% in 2024, then crashed 19598.76% in 2025.
  • Year by year, Revenue stood at -$37793.0 in 2021, then surged by 1658.47% to $588994.0 in 2022, then plummeted by 99.63% to $2165.0 in 2023, then decreased by 9.19% to $1966.0 in 2024, then tumbled by 312.16% to -$4171.0 in 2025.
  • Business Quant data shows Revenue for ABVC at -$4171.0 in Q4 2025, $795950.0 in Q3 2025, and -$129413.0 in Q2 2025.